Brief: Clarity Pharmaceuticals To Commence Phase III Trial Of 64 Cu-Sartate In NETS
21/12/2025 22:32
Dec 22 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX: TO COMMENCE PHASE III TRIAL OF 64 CU-SARTATE IN NETS Further company coverage: CU6.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial